ESR1 and breast carcinoma: For further study, the in vivo therapeutic efficacy of CA800-PR in other types of HR+ breast cancers, including ESR-/PGR+, ESR+/PGR-, PGR+/HER2+, and PGR+/HER2- breast cancers, is now under investigation.